SCM
ALNY icon

Silverarc Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Silverarc Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,000
Closed -$5.83M – 81
2022
Q2 		$5.83M Buy
+40,000
New +$5.67M 1.8% 20

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Silverarc Capital Management's ALNY Position: Q4 2024 in Review

Silverarc Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 35,774 shares — an estimated $9.84M sold.

Silverarc Capital Management first reported a position in ALNY in Q3 2022 and held it in 5 quarters. The position peaked at $9.84M in Q3 2024. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • Silverarc Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 35,774 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $9.84M.
  • Silverarc Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • Silverarc Capital Management's Alnylam Pharmaceuticals position peaked at $9.84M in Q3 2024.
  • 594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.